Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism

Blood Purification
P GrützmacherP Scigalla

Abstract

In a European multicenter trial the weekly rates of increase in hematocrit and reticulocyte values were investigated in hemodialyzed patients with transfusion-dependent anemia treated with recombinant human erythropoietin (rHuEPO). Within a few months of therapy, the number of transfusion-dependent patients decreased to less than 5% of the group. Patients with aluminum overload indicated by elevated basal serum levels or elevated levels after a desferrioxamine challenge showed a significantly reduced response to rHuEPO. whereas in patients with elevated levels of parathyroid hormone a normal response to rHuEPO was found.

Citations

Jan 1, 1990·Annals of the New York Academy of Sciences·R C HiderE R Huehns
Jan 25, 2005·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Fumitake GejyoUNKNOWN Japanese Society for Dialysis Therapy
Jul 9, 2010·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Yoshiharu TsubakiharaTadao Akizawa
Sep 5, 2006·Seminars in Nephrology·Claudio Rigatto
Oct 9, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ylenia IngrasciottaUNKNOWN Italian Biosimilars Network (I-BioNetwork)
Mar 7, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.